Insmed Inc Stock Price, News & Analysis

Insmed (INSM) has announced plans for a significant public offering of common stock, aiming to raise $650 million. The biopharmaceutical company will also grant underwriters a 30-day option to purchase an additional $97.5 million worth of shares. Goldman Sachs & Co. LLC and Leerink Partners are serving as joint book-running managers for the offering. The offering will be made under Insmed's existing shelf registration statement that became effective on May 19, 2023. The completion of the offering is subject to market conditions, with no guarantee of its final size or terms.

Insmed (NASDAQ: INSM) reported positive topline results from its Phase 2b study of TPIP (treprostinil palmitil inhalation powder) for pulmonary arterial hypertension (PAH). The once-daily therapy met its primary endpoint with a 35% placebo-adjusted reduction in pulmonary vascular resistance (p<0.001). Secondary endpoints showed a 35.5-meter improvement in six-minute walk distance (p=0.003) and 60% reduction in NT-proBNP concentrations (p<0.001). The study involved 102 patients across 44 sites, with 75% reaching the maximum dose of 640 µg daily. TPIP demonstrated sustained 24-hour efficacy and was well-tolerated, with cough (40.6%) and headache (31.9%) as the most common side effects. Based on these results, Insmed plans to initiate Phase 3 trials for PH-ILD by end of 2025 and PAH in early 2026.

Insmed announced inducement grants to 150 new employees under its 2025 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). On May 30, 2025, the employees received 155,822 restricted stock units and options to purchase 16,860 shares at $69.73 per share. The restricted stock units follow a four-year vesting schedule with 25% vesting annually. The stock options have a 10-year term with 25% vesting after the first year and 12.5% vesting every six months thereafter, subject to continued employment.

Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company, has announced its participation in the 2025 Goldman Sachs Annual Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 11, 2025, at 9:20 a.m. ET in Miami. Investors and interested parties can access the live webcast through Insmed's investor relations website section at www.insmed.com. The webcast recording will remain available for 30 days after the event concludes.

Insmed presented new data from three prespecified subgroup analyses of the Phase 3 ASPEN trial for brensocatib in non-cystic fibrosis bronchiectasis (NCFBE) at ATS 2025. The analyses demonstrated consistent efficacy and safety across three key patient populations: adolescents, patients on macrolide therapy, and those with varying blood eosinophil levels. Key findings include: - In adolescents, both 10mg and 25mg doses reduced exacerbation rates (0.35 and 0.64 vs 0.87 placebo) - Patients on macrolide therapy showed lower exacerbation rates with brensocatib (10mg: 0.97/1.21; 25mg: 0.98/1.21) vs placebo (1.23/1.54) - Across blood eosinophil levels, both doses reduced exacerbation rates and improved lung function The company also presented findings on TPIP for PH-ILD and real-world data for ARIKAYCE in MAC lung disease.

Insmed reported strong Q1 2025 financial results, with ARIKAYCE revenue reaching $92.8M, up 23% YoY. The company maintained its 2025 ARIKAYCE revenue guidance of $405-425M. Key developments include: the FDA's acceptance of brensocatib's NDA for bronchiectasis with a PDUFA date of August 12, 2025; completion of TPIP's Phase 2b study in PAH with data expected June 2025; and completed enrollment in Phase 2b BiRCh study for brensocatib in CRSsNP. Despite revenue growth, Insmed reported a net loss of $256.6M ($1.42/share) vs $157.1M in Q1 2024, primarily due to increased R&D and SG&A expenses. The company maintains a strong balance sheet with $1.2B in cash and investments and plans to redeem $569.5M of convertible notes in June 2025.

Insmed (Nasdaq: INSM), a global biopharmaceutical company focused on developing first- and best-in-class therapies for serious diseases, has announced its upcoming presentation at the BofA Securities 2025 Health Care Conference.

The presentation is scheduled for Tuesday, May 13, 2025, at 2:20 p.m. PT in Las Vegas. Interested parties can access the live webcast through the investor relations section of Insmed's website at www.insmed.com.

Key Details:

• Event: BofA Securities 2025 Health Care Conference
• Location: Las Vegas
• Date & Time: May 13, 2025, 2:20 p.m. PT
• Webcast Duration: Archive available for 30 days post-event

Insmed (INSM) has announced the redemption of all remaining outstanding 0.75% Convertible Senior Notes Due 2028, totaling $569.5 million. The redemption is scheduled for June 6, 2025, with a redemption price of approximately $1,000.10 per $1,000 principal amount, including accrued and unpaid interest.

Noteholders have the option to convert their notes into common stock until June 4, 2025. The current conversion rate is 30.7692 shares per $1,000 principal amount, equivalent to a conversion price of $32.50 per share. If all notes are converted, up to 17,523,336 shares of common stock will be issued.

Insmed (NASDAQ: INSM) announced the publication of positive Phase 3 ASPEN study results for brensocatib in the New England Journal of Medicine. The landmark study, the largest clinical trial ever conducted in bronchiectasis, demonstrated statistically significant results in treating non-cystic fibrosis bronchiectasis, a chronic inflammatory pulmonary disease.

The study met its primary endpoint with both 10mg and 25mg doses showing reduced annualized exacerbation rates (1.02 and 1.04) compared to placebo (1.29). The 25mg dose notably demonstrated a significant reduction in lung function decline. The drug was well-tolerated, with common side effects including COVID-19, nasopharyngitis, cough, and headache.

Brensocatib is currently under Priority Review with the FDA, with a target action date of August 12, 2025. If approved, it would become the first approved therapy for bronchiectasis and the first approved DPP1 inhibitor.